Cargando…

Immunodeficiency and autoimmunity during biological disease-modifying antirheumatic drug therapy

Biological disease-modifying antirheumatic drugs target specific components of the immune response related to pathogenesis of autoimmune and inflammatory diseases. Introduction of biologic therapies has enabled better disease control than conventional drugs and thus a reduction in comorbidity and mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Czekalska, Anna, Majewski, Dominik, Puszczewicz, Mariusz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2019
Materias:	Review Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6753594/ https://www.ncbi.nlm.nih.gov/pubmed/31548748 http://dx.doi.org/10.5114/reum.2019.87616

Ejemplares similares

The exposure to biologic and targeted synthetic disease-modifying antirheumatic drugs in pregnancy and lactation
por: Góralczyk, Alicja, et al.
Publicado: (2020)

Rheumatic diseases induced by drugs and environmental factors: the state-of-the-art – part one
por: Niklas, Karolina, et al.
Publicado: (2016)

Rheumatic diseases induced by drugs and environmental factors: the state-of-the-art – part two
por: Niklas, Karolina, et al.
Publicado: (2016)

Are biologics more effective than classical disease-modifying antirheumatic drugs?
por: Nurmohamed, Michael T, et al.
Publicado: (2008)

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2013)

Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region
por: Kaló, Zoltán, et al.
Publicado: (2017)

Development and Validation of Adherence Score for Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs
por: Abdul Razak, Salmi, et al.
Publicado: (2020)

The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis
por: Hasegawa, Eriko, et al.
Publicado: (2023)

Vitamin D supply in patients with rheumatic diseases in Poland – a pilot study
por: Runowska, Marta, et al.
Publicado: (2021)

Retroperitoneal fibrosis – the state-of-the-art
por: Runowska, Marta, et al.
Publicado: (2016)

Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis
por: Marra, Fawziah, et al.
Publicado: (2016)

IS BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG USE IN PATIENTS WITH AUTOIMMUNE DISEASES A RISK FACTOR FOR SEVERE SARS-COV-2 INFECTION?
por: WAQAR, HAFIZA HAREEM, et al.
Publicado: (2022)

Antinuclear antibodies in autoimmune and allergic diseases
por: Grygiel-Górniak, Bogna, et al.
Publicado: (2017)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
por: Smolen, Josef S, et al.
Publicado: (2010)

Predictive Factors of Response to Biological Disease Modifying Antirheumatic Drugs: Towards Personalized Medicine
por: Daïen, Claire I., et al.
Publicado: (2014)

Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs
por: Sruamsiri, Rosarin, et al.
Publicado: (2018)

Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan
por: Sullivan, Emma, et al.
Publicado: (2020)

Evaluation of Access Disparities to Biologic Disease-Modifying Antirheumatic Drugs in Rural and Urban Communities
por: Peterman, Nicholas J, et al.
Publicado: (2022)

Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis
por: Nash, Peter, et al.
Publicado: (2021)

Spectrum of infections occurring in patients of autoimmune rheumatic diseases on treatment with biological versus conventional disease-modifying antirheumatic drugs: A comparative study
por: Gupta, Partisha, et al.
Publicado: (2022)

Hypersensitivity reactions to biologic disease modifying antirheumatic drugs: experience from the TTSH Singapore biologics registry
por: Thong, Bernard, et al.
Publicado: (2014)

Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI
por: Marona, Jose, et al.
Publicado: (2020)

Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia
por: Fletcher, Ashley, et al.
Publicado: (2022)

Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
por: Cho, Soo-Kyung, et al.
Publicado: (2023)

Molecular mechanisms of resistance to disease modifying antirheumatic drugs (DMARDs)
por: Jansen, G, et al.
Publicado: (2002)

Influence of biologic and conventional disease-modifying antirheumatic drugs on COVID-19 incidence among rheumatic patients during the first and second wave of the pandemic in Iran
por: Sahebari, Maryam, et al.
Publicado: (2022)

Premise: traditional disease-modifying antirheumatic drugs are less effective and safe than targeted therapy with biologic response modifiers in rheumatoid arthritis
por: Fleischmann, R
Publicado: (2003)

Comparison of Biologic Disease-Modifying Antirheumatic Drug Therapy Persistence Between Biologics Among Rheumatoid Arthritis Patients Switching from Another Biologic
por: Johnston, Stephen S., et al.
Publicado: (2014)

Comparison of the Effect of Disease: Modifying Antirheumatic Drugs Alone or in Combination with Biologic Drugs in the Outcome of Patients with Rheumatoid Arthritis
por: Mousavi, Maryam, et al.
Publicado: (2019)

Effectiveness and drug retention of biologic disease modifying antirheumatic drugs in Korean patients with late onset ankylosing spondylitis
por: Kim, Se Hee, et al.
Publicado: (2021)

Assessment of anti-CarP antibodies, disease activity and quality of life in rheumatoid arthritis patients on conventional and biological disease-modifying antirheumatic drugs
por: Kumar, Sudhir, et al.
Publicado: (2017)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
por: Smolen, Josef S, et al.
Publicado: (2014)

Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis – a systematic review
por: Kingsley, Gabrielle H, et al.
Publicado: (2015)

An Analysis of the Biological Disease-modifying Antirheumatic Drug-free Condition of Adalimumab-treated Rheumatoid Arthritis Patients
por: Ito, Satoshi, et al.
Publicado: (2018)

Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis
por: Jin, Yinzhu, et al.
Publicado: (2017)

Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs
por: Charles-Schoeman, Christina, et al.
Publicado: (2016)

Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis
por: Gladman, Dafna D., et al.
Publicado: (2020)

Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns for Rheumatoid Arthritis Among United States Physicians
por: Sullivan, Emma, et al.
Publicado: (2020)

Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan
por: Li, Ko-Jen, et al.
Publicado: (2021)

The Biological Disease-Modifying Antirheumatic Drugs and the Risk of Cardiovascular Events: A Systematic Review and Meta-Analysis
por: Hu, Suiyuan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l3c4iqv035ioc8trks0mh7tnci